<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984384</url>
  </required_header>
  <id_info>
    <org_study_id>PCS-1511-32745</org_study_id>
    <nct_id>NCT02984384</nct_id>
  </id_info>
  <brief_title>PREVENTion of Clot in Orthopaedic Trauma</brief_title>
  <acronym>PREVENT CLOT</acronym>
  <official_title>PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Major Extremity Trauma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Major Extremity Trauma Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of Low Molecular Weight Heparin
      (LMWH) compared to Aspirin in preventing death and clinically important pulmonary blood clots
      in patients who sustain trauma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the efficacy of Low Molecular Weight Heparin (LMWH) (Enoxaparin) compared to
      Aspirin in the use of preventing death and clinically important blood clots in the lungs in
      patients who sustain trauma will be investigated. The following comparisons between aspirin
      and the LMWH are described in the specific aims below:

      Specific Aim 1: Assess the proportion of patients who sustain death, clinically significant
      pulmonary embolism, or complication after orthopaedic trauma treated with injectable LMWH
      compared to those treated with aspirin.

      Hypothesis 1a: The mortality rate will be non-inferior in the aspirin group Hypothesis 1b:
      The rate of clinically significant PE will be non-inferior in the aspirin group Hypothesis
      1c: The rate of complications will be superior (i.e., lower) in the aspirin group Specific
      Aim 2: Assess satisfaction with care in orthopaedic trauma patients treated with injectable
      LMWH compared to those treated with aspirin Hypothesis2a : Satisfaction will be superior in
      the aspirin group Specific Aim 3: Document out of pocket patient costs in orthopaedic trauma
      patients treated with injectable LMWH compared to those treated with aspirin Hypothesis3a :
      Out of pocket costs will be lower in the aspirin group Specific Aim 4: Examine the proportion
      of minor clot events that are less important to patients (clots in the proximal legs,
      incidental PE) in orthopaedic trauma patients treated with injectable LMWH compared to those
      treated with aspirin.

      Hypothesis4a : The rate will be non-inferior in the aspirin group Specific Aim 5: Examine the
      proportion of minor clot events that are less important to patients (clots in the proximal
      legs, incidental PE) in orthopaedic trauma patients treated with injectable LMWH compared to
      those treated with aspirin.

      Hypothesis 5a: The rate will be non-inferior in the aspirin group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
    <description>Number of death and relatedness of death to a pulmonary embolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically important pulmonary embolism</measure>
    <time_frame>3 months</time_frame>
    <description>Detected pulmonary embolism that are life threatening or symptom causing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>3 months</time_frame>
    <description>Complications associated with trauma and trauma treatment:
Wound drainage, hematoma or seroma of an orthopaedic injury requiring reoperation
Diagnosis of deep surgical site infection of an orthopaedic injury requiring operation.
Diagnosis of a deep surgical site infection of an orthopaedic injury, not requiring operation
Clinically overt bleed with a &gt; 2g/dL drop in Hb or requiring &gt; 2 unit transfusion
GI bleed
Other bleeding complications following study enrollment and receipt of first dose of study medication requiring procedure
Lower extremity deep venous thrombosis (DVT) distal to knee
Lower extremity or pelvic DVT proximal to knee
Other DVT
Studies ordered related to concerns for bleeding or venous thromboembolism event</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12980</enrollment>
  <condition>Blood Clot</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Low Molecular Weight Heparin (LMWH)-Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 30 mg enoxaparin, twice a day via injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid (ASA)-Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteral ingestion or administration of 81 mg ASA, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.</description>
    <arm_group_label>Acetylsalicylic acid (ASA)-Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin (LMWH)</intervention_name>
    <description>The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.</description>
    <arm_group_label>Low Molecular Weight Heparin (LMWH)-Enoxaparin</arm_group_label>
    <other_name>Enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Trauma patients who are at increased risk of blood clots from their orthopaedic
             traumatic injury (operatively treated extremity injuries and all pelvis or acetabulum
             fractures that are treated either operatively or non operatively) and for whom a
             prophylactic blood thinner regimen would be standard of care at their institution.

          -  18 years or older

        Exclusion Criteria:

          -  Patients who present to the hospital more than 48 hours post injury

          -  Patients who received more than 2 doses of LMWH or Aspirin for initial prophylaxis

          -  Patients on long term blood thinners (other than low-dose aspirin or platelet
             inhibitors such as Plavix or Aggrenox)

          -  Patients who have had a VTE within the last 6 months

          -  Patients on therapeutic (as opposed to prophylactic) blood thinners for an acute issue
             at the time of admission

          -  Patients who have a newly diagnosed indication for therapeutic blood thinners (for
             example vascular injury) that will require therapeutic anticoagulation for more than
             one week

          -  Patients who cannot receive either of the study medications due to an allergy (history
             of heparin induced thrombocytopenia, allergy to aspirin, or NSAIDs) or other medical
             contraindication to blood thinners

          -  Patients who are on higher dose aspirin (&gt;81 mg once a day or higher) for medical
             reasons or who will be treated with higher dose aspirin

          -  Patients with underlying chronic clotting disorders (i.e. Factor V Leiden,
             hyperhomocysteinemia, Protein C and S deficiency) that require full dose
             anticoagulation or are a contraindication to venous thromboembolism chemoprophylaxis

          -  Patients with end stage renal disease or impaired creatinine clearance &lt;30 ml/min at
             time of randomization(note: creatinine clearance does not need to be documented if
             prescribing physician would order medication without test as SOC)

          -  Pregnant or lactating patients

          -  Patients contraindicated for any reason for either medicine

          -  Prisoners

          -  Patients who do not speak either English or Spanish

          -  Patients may be excluded for other reasons at the discretion of the treating
             physician; the reason for exclusion must be documented on the screening form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O'Toole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renan Castillo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tara Taylor, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine Frey, PhD, MPH, RN</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Taylor, MPH</last_name>
    <phone>410-614-6081</phone>
    <email>ttaylo56@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan O'Hara, MHA</last_name>
    <email>nohara@umoa.umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Seach</last_name>
      <email>aseach@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Boulton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bellal Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Ryder Trauma Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinorah Rodriquez</last_name>
      <email>dinorah@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Zych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanya Zakrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakye Deeter</last_name>
      <email>lakedwar@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Gaski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Zarzaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Degani</last_name>
      <email>ydegani@umoa.umm.edu</email>
    </contact>
    <investigator>
      <last_name>Robert O'Toole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McTague</last_name>
      <email>MMCTAGUE@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Michael Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Velmahos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Hydrick</last_name>
      <email>jhydrick@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Partrick Bergin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Kutcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ressler</last_name>
      <email>Daniel.R.Ressler@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Leah Gitajn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt Rhynhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Seymour, PhD</last_name>
      <email>Rachel.Seymour@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Bosse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Christmas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Holden</last_name>
      <email>mholden@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Eben Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Preston Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Breslin</last_name>
      <email>mbreslin@metrohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Fraifogl</last_name>
      <email>jfraifogl@metrohealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Heather Vallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffery Claridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital, Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jean Crisco</last_name>
      <email>mjcrisco@universityorthopedics.com</email>
    </contact>
    <investigator>
      <last_name>Roman Hayda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Lueckal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, RegionOne Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Waddle-Smith</last_name>
      <email>lwaddle@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>John Weinlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Croce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Trochez</last_name>
      <email>karen.m.trochez@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>William Obremskey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Guillamondegui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Galpin</last_name>
      <email>Matthew.Galpin@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Gary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Cotton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie DeLeon</last_name>
      <email>stephanie.deleon.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Patrick Osborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Agel</last_name>
      <email>bagel@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Firoozabadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Cuschieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Harrison</last_name>
      <email>tharriso@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Prism Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul McBeth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University, Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johal Herman, MD</last_name>
      <email>hermanjohal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Johal Herman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Blood clot</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Blood clot prevention</keyword>
  <keyword>trauma patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

